Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Plasmid structure for expressing CD19CAR and knocking down T cell surface PD-1 expression simultaneously and construction method thereof

A cell surface, PD-1 technology, applied in the biological field, can solve the problems of unsatisfactory CART cell effect, decreased CART cell function, impaired tumor clearance ability, etc., to achieve the effect of less apoptosis and better cell proliferation ability

Inactive Publication Date: 2018-08-21
WUHAN BIO RAID BIOTECH CO LTD
View PDF5 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] CART cell immunotherapy has shown great potential in preclinical and clinical trials of hematological malignancies, but due to the inhibitory effect of immune checkpoints in the tumor microenvironment, the effect of CART cells in the treatment of solid tumors has been unsatisfactory, among which PD The -1 / PD-L1 pathway has been shown to be associated with T cell exhaustion, leading to CART cell dysfunction and impaired tumor clearance

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Plasmid structure for expressing CD19CAR and knocking down T cell surface PD-1 expression simultaneously and construction method thereof
  • Plasmid structure for expressing CD19CAR and knocking down T cell surface PD-1 expression simultaneously and construction method thereof
  • Plasmid structure for expressing CD19CAR and knocking down T cell surface PD-1 expression simultaneously and construction method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0047] Example 1 Screening of backbone plasmids capable of co-expressing CAR and shRNA, GFP expression in K-562 human chronic myelogenous leukemia cells can be effectively knocked down by pH1 constructs

[0048] In order to simplify the experiment, we first constructed a GFP+K562 stable cell line by lentiviral transduction and puromycin screening, then replaced the CAR sequence with the mCherry fluorescent sequence, and constructed three backbone plasmids p H1 and p MSCV using different promoters and plasmid structures and pEF1α. The three plasmids were transduced into the GFP+K-562 human chronic myelogenous leukemia cell line by lentivirus, and the fluorescence expression intensity of mCherry and GFP was detected by flow cytometry. Experimental results such as figure 2 As shown, p H1+K562 showed a more obvious down-regulation of GFP expression than the other two, indicating that this backbone can allow the simultaneous high-efficiency expression of shRNA and the target CAR ...

Embodiment 2

[0049] Example 2 Screening and verification of the most efficient anti-PD-1 shRNA sequence in jurkat cell lines and human CD3+ T cells

[0050] Preliminary experiments proved that Jurkat cell line and human CD3+ T cells can also be induced to express PD-1 by human T cell activation immunomagnetic beads CD3 / CD28 magnetic beads. We used ten shRNA sequences targeting PD-1 mRNA to knock down its expression, as shown in Table 1, to construct expression plasmids, using GFP fluorescence as a marker. Then ten plasmids were transduced into the Jurkat cell line by lentivirus, stimulated with CD3 / CD28 magnetic beads, and flow cytometry was used to detect the GFP fluorescence and PD-1 expression on the surface of Jurkat cells. The experimental results showed that in activated jurkat cells, PD1-1, PD1-4, PD1-8 and PD1-10 all showed better PD-1 knockdown effects, such as image 3 shown.

[0051] In order to verify the role in human T cells, we concentrated and purified the lentiviruses of...

Embodiment 3

[0055] Example 3 Reduced expression of PD-1 on the surface of CD19-CAR T cells carrying anti-PD-1 shRNA

[0056] The two shRNA sequences PD1-1 and PD1-8 obtained by screening were subcloned into the plasmid structure of the pLVX-IRES-puro standard vector using the structure of pH1 and the third-generation anti-CD1941BB+CD28CAR. Using the basic CD19-CAR as a negative control group, through lentiviral packaging, the concentrated and purified high and low levels of virus were used to transduce CD3+ T cells stimulated by CD3 / CD28 magnetic beads in healthy volunteers. 72 hours after transduction, flow cytometry was used to detect the conversion effect. Three groups of samples (CD19-control; CD19-PD1-1; CD19-PD1-8) were collected at 24 hours and 72 hours after the transduction to extract total RNA, and the relative quantitative q-PCR analysis was performed for T PD-1 mRNA expression level in cells (GAPDH as internal reference). The experimental results showed that compared with the...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a plasmid structure for expressing CD19CAR and knocking down T cell surface PD-1 expression simultaneously. The plasmid structure comprises an H1 promoter, an anti-PD-1shRNA sequence started by the H1 promoter, an EF1alpha promoter and a three-generation CD19CAR sequence started by the EF1alpha promoter that are connected in series in order. The three-generation CD19CAR sequence consists of a CD19 single chain variable region, a human CD8alpha hinge region, a human CD28 transmembrane region and an intracellular region, a human 41BB intracellular region and a human CD3zeta intracellular region that are connected in series. The plasmid structure provided by the invention is transduced into T cells by a lentivirus, and the CART cell production process is significantlysimplified than using CRISPR / Cas9 for knockout of PD-1. Moreover, the CART cells show enhanced tumor cytotoxicity killing ability and increased persistent cell repair and cytokine secretion ability after antigenic stimulation in vitro.

Description

technical field [0001] The invention belongs to the field of biotechnology, and in particular relates to a plasmid structure capable of simultaneously expressing CD19 CAR and knocking down the expression of PD-1 on the surface of T cells and a construction method thereof. technical background [0002] The U.S. Food and Drug Administration (FDA) approved the first gene therapy on August 30, 2017, when they approved Kymriah (tisagenlecleucel) to treat some children and young adults with acute lymphoblastic leukemia (ALL). Kymriah is a genetically modified autologous T cell immunotherapy known as chimeric antigen receptor T cell (CART) immunotherapy. The most common CARs include an antigen recognition sequence, such as a single-chain variable fragment (scFv) of a monoclonal antibody (mAb), and a TCRζ chain mainly derived from the intracellular signaling domain of activated T cells (Lee DW, Barrett DM , MackallC, Orentas R, Grupp SA. The Future Is Now: Chimeric Antigen Receptor...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12N15/63C12N15/66
CPCC12N15/63C12N15/66
Inventor 张同存顾潮江潘丽娟
Owner WUHAN BIO RAID BIOTECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com